Neupogen (Filgrastim)

Filgrastim, the active ingredient in Neupogen, is a granulocyte colony‑stimulating factor presented as an injectable solution for subcutaneous use. It treats chemotherapy‑induced neutropenia, neutropenia associated with bone‑marrow transplantation, severe chronic neutropenia and agranulocytosis.

GNH USA supplies Neupogen as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide.

Neupogen (filgrastim) is used to stimulate neutrophil production in patients with conditions that cause low white‑blood‑cell counts.

- Chemotherapy‑induced neutropenia: shortens the duration of neutropenia and reduces infection risk. - Neutropenia associated with bone‑marrow transplantation: supports engraftment and accelerates neutrophil recovery. - Severe chronic neutropenia: raises neutrophil counts and lowers the frequency of infections. - Agranulocytosis: hastens restoration of normal neutrophil levels.

Filgrastim may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Bone pain: aching discomfort, often in the limbs or back. - Injection site reactions: redness, swelling or mild tenderness. - Fever: low‑grade temperature elevation. - Headache: mild to moderate intensity. - Fatigue: general feeling of tiredness.

Serious or Rare Side Effects: - Splenic rupture: sudden left‑upper‑quadrant pain, possible shock. - Acute respiratory distress syndrome: severe breathing difficulty. - Anaphylaxis: rapid onset of hives, swelling, airway compromise. - Leukocytosis: excessively high white‑blood‑cell count.

Before initiating filgrastim therapy, clinicians should consider several safety measures.

- Monitor blood counts: perform regular CBCs to track neutrophil response. - Assess splenic size: watch for left‑upper‑quadrant pain that may signal splenomegaly. - Avoid in patients with hypersensitivity: discontinue if severe allergic reaction occurs. - Use caution in sickle‑cell disease: filgrastim may precipitate vaso‑occlusive crises. - Pregnancy and lactation: safety not established; weigh benefits against potential risks. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Filgrastim can interact with other medicines, requiring attention to avoid reduced efficacy or increased toxicity.

Major Interactions (Avoid): - Concurrent myelosuppressive chemotherapy: may mask true neutrophil recovery. - Cytarabine: additive myelosuppressive effect. - High‑dose corticosteroids: may diminish filgrastim activity.

Moderate Interactions (Monitor Closely): - Antibiotics (e.g., quinolones): may alter infection risk assessment. - Live attenuated vaccines: immune response may be blunted. - ACE inhibitors: possible increased risk of hypotension with rapid neutrophil rise.